Document Detail

Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
MedLine Citation:
PMID:  20951922     Owner:  NLM     Status:  MEDLINE    
The pharmacokinetics and pharmacodynamics of standard interferon alfa-2a and interferon alfa-2b are substantially altered by pegylation. The size, geometry, and site of attachment of the PEG moiety affect the pharmacokinetics and pharmacodynamics as evidenced by the different absorption, volume of distribution, and clearance of the linear 12-kDa peginterferon alfa-2b and the branched 40-kDa peginterferon alfa-2a. Despite these differences, the clinical efficacy, safety, and tolerability of the 2 peginterferons are similar. However, evidence exists that peginterferon alfa-2 plus ribavirin is associated with small but significantly higher sustained virological response rates compared with peginterferon alfa-2b. This article discusses the pharmacokinetics and pharmacodynamics of the 2 peginterferons and their combination with ribavirin.
Mazen Noureddin; Marc G Ghany
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review    
Journal Detail:
Title:  Gastroenterology clinics of North America     Volume:  39     ISSN:  1558-1942     ISO Abbreviation:  Gastroenterol. Clin. North Am.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-10-18     Completed Date:  2011-02-04     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  8706257     Medline TA:  Gastroenterol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  649-58     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Inc.
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B-16, 10 Center Drive, MSC 1800, Bethesda, MD 20892-1800, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / pharmacology*,  therapeutic use
Clinical Trials as Topic
Drug Therapy, Combination
Hepatitis C, Chronic / drug therapy*
Interferon-alpha / pharmacology*,  therapeutic use
Polyethylene Glycols / pharmacology*,  therapeutic use
Recombinant Proteins
Ribavirin / pharmacology*,  therapeutic use
Grant Support
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 76543-88-9/interferon alfa-2a; 99210-65-8/interferon alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The gastrointestinal complications of oncologic therapy.
Next Document:  New pharmacologic therapies in chronic hepatitis B.